BeiGene prices Hong Kong listing

BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) raised HK$7.1 billion (US$902.7 million) early Thursday through the sale of 65.6 million shares at HK$108 in its listing on the Hong Kong stock exchange. The cancer company, which priced the offering toward the higher end of its proposed range of HK$94.40-HK$111.60, expects to start trading on Aug. 8.

At the HK$103 midpoint, the biotech would have raised HK$6.8 billion (US$861 million). Underwriters included Morgan Stanley, Goldman Sachs (Asia), Credit Suisse (Hong Kong), CLSA, CICC, Deutsche Bank, UBS and China Renaissance (see "BeiGene's Proposed HKEX Listing Could Rake in Over $900M")...